Invention Grant
- Patent Title: Use of tetrahydrobiopterin as a marker and a therapeutic agent for fabry disease
- Patent Title (中): 使用四氢生物喋呤作为标记物和药物治疗剂
-
Application No.: US12757420Application Date: 2010-04-09
-
Publication No.: US08410101B2Publication Date: 2013-04-02
- Inventor: Raphael Schiffmann , Teodoro G. Bottiglieri , Erland Arning , David F. Moore
- Applicant: Raphael Schiffmann , Teodoro G. Bottiglieri , Erland Arning , David F. Moore
- Applicant Address: US TX Dallas
- Assignee: Baylor Research Institute
- Current Assignee: Baylor Research Institute
- Current Assignee Address: US TX Dallas
- Agency: Fulbright & Jaworski L.L.P.
- Main IPC: A61P43/00
- IPC: A61P43/00 ; G01N33/20
Abstract:
Blood and tissue markers of the metabolic status, risk of health complications in Fabry disease patients and as a biomarker to follow the efficacy of treatment in animal models and patients with Fabry disease comprising tetrahydrobiopterin (BH4), precursors and metabolites of BH4, and other related co-factors is disclosed herein. The present invention further describes the use of BH4 therapy as a treatment option for Fabry disease to prevent, slow or reverses vascular cardiac and renal manifestations of Fabry disease.
Public/Granted literature
- US20100260747A1 Use of Tetrahydrobiopterin as a Marker and a Therapeutic Agent for Fabry Disease Public/Granted day:2010-10-14
Information query
